Dr Liz Dallimore, Managing Director of Argenica Therapeutics, explains why securing an EMA paediatric waiver for ARG-007 materially simplifies the
Argenica Therapeutics (ASX:AGN) clears a major regulatory hurdle with positive drug-drug interaction results for ARG-007, bringing the company closer to
Liz Dallimore says the independent MCAo data marks a pivotal confirmation of ARG 007’s neuroprotective activity and sharpens the company’s
Dr Liz Dallimore, says the company’s latest Phase 2 trial results for ARG-007 demonstrate encouraging trends in patient recovery and
Argenica Therapeutics (ASX:AGN) has released promising data from its Phase 2 clinical trial of ARG-007, a neuroprotective peptide designed to
Argenica Therapeutics may have cracked the code on treating brain injury, with a ferret study showing its lead drug ARG-007
Argenica Therapeutics has secured a new US patent that positions its lead drug, ARG-007, at the forefront of preventing stroke
Argenica Therapeutics’ ARG-007 has demonstrated compelling neuroprotective effects in preclinical models of traumatic brain injury, reducing brain cell damage and
Argenica Therapeutics (ASX:AGN) moves closer to a potential breakthrough in stroke treatment as its Phase 2 trial of ARG-007 nears
Argenica Therapeutics (ASX:AGN) has dosed 80% of patients in its Phase 2 trial for ARG-007, a promising stroke therapy, with
Argenica Therapeutics advances its stroke treatment with ARG-007, achieving a key safety milestone in its Phase 2 trial, signalling promising
